The APC gene is a tumor suppressor gene located on chromosome 5 that acts as one of the body’s primary brakes against colorectal cancer. It produces a protein responsible for controlling cell growth in the lining of the colon and rectum. When both copies of this gene are functioning normally, they keep cells from dividing too quickly. When the gene is mutated, that brake fails, and cells can begin growing out of control. Somatic APC mutations are found in more than 80% of sporadic colorectal cancers, making it one of the most commonly altered genes in any human cancer.
How the APC Protein Controls Cell Growth
The APC protein’s best-known job is regulating a signaling system called the Wnt pathway, which tells cells when to grow and divide. In a healthy cell, APC is part of a protein complex that tags a molecule called beta-catenin for destruction. Beta-catenin is a growth signal: when it accumulates inside a cell, it enters the nucleus and switches on genes that drive cell division. APC prevents that accumulation by helping enzymes attach chemical markers to beta-catenin, flagging it for breakdown by the cell’s recycling machinery.
When APC is mutated and can no longer do this job, beta-catenin builds up unchecked. It floods the nucleus, locks onto DNA-binding proteins, and activates a cascade of growth-promoting genes. The result is a cell that keeps dividing when it should stop, the first step toward a polyp or tumor.
APC does more than just manage Wnt signaling, though. It helps organize the internal scaffolding cells use to pull chromosomes apart during division, ensuring each new cell gets the correct number of chromosomes. It also helps establish cell polarity, the front-to-back orientation that keeps cells migrating in the right direction, and it can directly block DNA replication. These additional roles mean that losing APC doesn’t just make cells grow faster; it makes them genetically unstable and prone to accumulating further mutations.
Inherited Mutations and Familial Adenomatous Polyposis
People who inherit a mutated copy of the APC gene from a parent develop a condition called familial adenomatous polyposis, or FAP. Because the mutation follows an autosomal dominant inheritance pattern, only one defective copy is needed to cause the disease, and each child of an affected parent has a 50% chance of inheriting it. In about 75 to 80% of FAP cases, the person has a parent who also had the condition. The remaining cases arise from new, spontaneous mutations.
Classic FAP is defined by the development of 100 or more adenomatous polyps in the colon and rectum, though many patients grow hundreds or even thousands. These polyps typically begin appearing in the teenage years. Without surgical removal of the colon, the lifetime risk of colorectal cancer approaches 100% by age 40. FAP is the second most common inherited polyposis syndrome, with an estimated incidence of 1 in 5,000 to 1 in 18,000 people. It affects men and women equally and accounts for roughly 1% of all colorectal cancer cases.
Attenuated FAP
A milder form called attenuated FAP (AFAP) involves fewer than 100 polyps, with an average of about 30. These polyps tend to cluster in the upper portion of the colon rather than being spread throughout, and the timeline is shifted: cancer development is delayed by 10 to 20 years compared to classic FAP. The lifetime cancer risk is still high, around 80% by age 80, but the later onset gives more time for screening and intervention.
APC Mutations in Sporadic Colorectal Cancer
You don’t need to inherit a faulty APC gene to be affected by it. In the general population, APC mutations that arise spontaneously in colon cells over a person’s lifetime are the initiating event in an estimated 80 to 85% of sporadic (non-inherited) colorectal cancers. Loss of one copy of the chromosome region containing APC is reported in 30 to 40% of these tumors as well. This makes APC loss one of the earliest and most consistent genetic changes on the path from normal tissue to colon cancer, a role sometimes described as the “gatekeeper” of colorectal cancer development.
Effects Beyond the Colon
APC mutations don’t only affect the colon. A constellation of extra-colonic features, historically grouped under the name Gardner syndrome, can appear in people with inherited APC mutations. These include osteomas (benign bone growths, often on the jaw or skull), extra teeth or other dental abnormalities, desmoid tumors in soft tissue, lipomas, fibromas, and cysts beneath the skin. Some patients develop a characteristic change in the retina called congenital hypertrophy of the retinal pigment epithelium, which an eye exam can detect even in childhood. People with Gardner syndrome also face increased risks of stomach and liver cancer.
Desmoid tumors deserve special mention because, while technically noncancerous, they can grow aggressively into surrounding tissue and become a significant source of complications. They sometimes require chemotherapy to shrink or stabilize.
Screening for APC Mutation Carriers
Because polyps in classic FAP can appear so early, current guidelines recommend that children with a known APC mutation or a family history of FAP begin annual colonoscopy screening between ages 10 and 12. This early, frequent monitoring allows doctors to track polyp growth and plan the timing of preventive surgery before any polyp has the chance to become cancerous.
For people carrying certain lower-risk APC variants, such as the I1307K mutation more common in people of Ashkenazi Jewish descent, screening can start later, at age 40 or 10 years before the age at which the youngest family member was diagnosed. The interval between screenings is also longer, typically every five years.
Genetic testing for APC mutations is widely available and is generally recommended for anyone with a strong family history of colorectal polyps or cancer at a young age. Identifying a mutation early changes the entire medical timeline for that person, shifting them from standard-risk screening schedules into a more intensive surveillance and prevention plan that can be lifesaving.